GlassScriptPhysician profile
Allen A Futral
NPI 1295839827
$5,107.78
in general payments reported to CMS, 2019-2025
45 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $360 · 2021: $496 · 2022: $767 · 2023: $1,315 · 2024: $603 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.63 |
| Travel and Lodging | $315.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $938.41 | 2019-2025 | Xtandi |
| Medtronic, INC. | $405.56 | 2021-2025 | Interstim |
| Pfizer INC. | $393.05 | 2019-2025 | |
| Procept Biorobotics Corporation | $373.09 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $340.51 | 2021-2023 | Urolift |
| Boston Scientific Corporation | $265.17 | 2019-2025 | Lithovue, Axonics |
| Myriad Genetic Laboratories, INC. | $257.46 | 2021-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $256.73 | 2023-2025 | Orgovyx, Gemtesa |
| Coloplast Corp | $179.84 | 2022-2025 | Titan |
| Janssen Biotech, INC. | $159.59 | 2019-2024 | Erleada |
| Dendreon Pharmaceuticals LLC | $141.74 | 2019-2022 | |
| Myovant Sciences INC. | $140.82 | 2021-2022 | |
| Tempus Ai, INC | $118.78 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $100.83 | 2020-2024 | Keytruda |
| Endo Pharmaceuticals INC. | $93.64 | 2019 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Futral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.